Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03377933
Other study ID # chbs230023-1
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 15, 2019
Est. completion date March 15, 2020

Study information

Verified date June 2019
Source Changhai Hospital
Contact Yi Qi Du, professor
Phone +8613801993592
Email duyiqi@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study assesses the efficacy and safety of treatment with two-week probiotics followed by a 10-day tetracycline- and furazolidone-containing quadruple regimen as rescue treatment for H. pylori infection. Eradication was evaluated using the 13C-urea breath test at 4 weeks after the end of therapy, and side effects were recorded. Besides study gene-level changes in the gastric microbiota following use of probiotics.


Description:

Currently the infection rate of H. pylori is high. H. pylori infection has a close relationship with human diseases , Among the patients with H. pylori infection, 100% have active gastritis, <10% show H. pylori related dyspepsia, 15%~20% develop into peptic ulcer, <1% ultimately evolve into gastric malignant tumor. H. pylori gastritis has been defined as an infective disease. Eradication of H. pylori plays an important role in the cure, reversal and delay of these diseases.

With the widespread eradication of H. pylori, antibiotics resistance rates are increasing seriously. The resistance of antibiotics results in the increase of H. pylori eradication failure rate. Choosing a safe and effective scheme for patients who have failed multiple times is a challenge for the clinicians.

Besides, both domestic and international consensuses point that the application of some probiotics can reduce adverse effects through regulating gastric microenvironment, and it is still controversial about whether probiotics can inhibit H. pylori to increase the eradication rate.

Investigators previously retrospectively analyzed 30 patients with H. pylori eradication failures at least two times given two-week compound Lactobacillus acidophilus followed with 10-day tetracycline- and furazolone- containing quadruple regimen, the ITT eradication rate was 92.1%, and 94.6% PP analysis. Side effects were mild mainly including dizziness, dry mouth and skin rash occurred in eight patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date March 15, 2020
Est. primary completion date March 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- All included patients were 18 to 70 years-old; negative for the urea breath test at least 4 weeks after last eradication treatment; and experienced at least 2 H. pylori eradication failures.

Exclusion Criteria:

- Patients were excluded if they presented with a severe comorbidity or a malignant tumor; had a known history of allergy to the drugs in the therapeutic regimen; used nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotic therapy, or bismuth salts up to 4 weeks before study inclusion; or were pregnant or breast-feeding.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Compound Lactobacillus acidophilus
Compound Lactobacillus acidophilus Tablet

Locations

Country Name City State
China Changhai hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Yiqi Du

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary gene-level changes in the gastric microbiota study gene-level changes through gene sequencing in the gastric microbiota following use of probiotics 2 weeks
Secondary eradication rate of the therapy using the 13C-urea breath test at 4 weeks after the end of therapy 4 weeks
Secondary the incidence of the adverse effects record the side effects on the 2 week, 4 week. 2 weeks, 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05073744 - Nalbuphine Versus Morphine for Perioperative Tumor Ablation Phase 4
Completed NCT03969641 - Safety of RIV4 Versus IIV4 in Pregnant Women Phase 4
Completed NCT05592951 - Safety and Tolerability of a Novel Amino-acid Based Hydration Drink in Healthy Volunteers N/A
Completed NCT04693429 - Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+ Phase 1
Completed NCT01636024 - To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594 Phase 1
Completed NCT01415102 - A First In Human Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Single Inhaled Doses Of PF-05212372. Phase 1
Completed NCT01243502 - A Study to Assess the Pharmacokinetics, Safety and Tolerability of CT327 in Healthy Male Volunteers Phase 1
Completed NCT06072170 - Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience Phase 1
Completed NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Recruiting NCT06060379 - Giochiamo 626 - Gaming for Health and Safety in Workplaces N/A
Recruiting NCT05298800 - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23 Phase 4
Completed NCT05188638 - Safety of Ascending Single and Multiple Doses of Nebulised SoftOx Inhalation Solution in Healthy Subjects Phase 1
Completed NCT05145621 - Oral Bio-equivalence Study Phase 1
Recruiting NCT05580159 - New Generation mRNA Booster Vaccine Against Emerging VOCs Phase 3
Not yet recruiting NCT04596956 - Safety and Efficacy of Sodium Bicarbonate Ringer Injection Phase 4
Completed NCT03033329 - Single Dose Escalation and Multiple Dose Escalation Trial of an Intravenous Formulation of MRX-4 Phase 1
Terminated NCT01929811 - NeoMET Study in Neoadjuvant Treatment of Breast Cancer Phase 2
Completed NCT01193335 - Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants. Phase 4
Completed NCT03300466 - A Study to Evaluate the Performance and Safety of GP0045 for Correction of Moderate to Severe Nasolabial Folds N/A
Active, not recruiting NCT05686161 - mRNA Booster Vaccine(SW-BIC-213) Compared With Pfizer andSinopharm Against Emerging VOCs Phase 3